European Ad Comm backs Merck's Keytruda for first-line treatment of certain type of lung cancer

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion recommending approval of Merck's (NYSE:MRK) KEYTRUDA (pembrolizumab) for the first-line treatment of adults patients with metastatic non-small lung cancer (NSCLC) whose tumors have high (50%+) PD-L1 expression with no EGFR or ALK mutations.

A final decision from the European Commission usually takes ~60 days.

KEYTRUDA is currently approved in Europe to treat NSCLC in patients previously treated with at least one line of chemo (it is also approved to treat melanoma).

Subscribe for full text news in your inbox